Back to top

Analyst Blog

Vivus, Inc. (VVUS - Analyst Report) recently announced that it has entered into an agreement with a Pharmakon Advisors managed investment fund for a $110 million non-equity financing. Vivus will initially draw $50 million for the commercialization of its obesity drug, Qsymia and other corporate activities.

As per the terms of the agreement, Vivus has an option to draw an additional $60 million by the end of 2013. Vivus will start repaying the debt from the second quarter of 2014 through second quarter of 2018. The quarterly payments will be based on a capped percentage on net sales of Qsymia subject to the maximum of a scheduled amount.

We note that Qsymia was approved by the US Food and Drug Administration (FDA) in Jul 2012. The FDA cleared Qsymia as an adjunct to a healthy diet (low on calories) and increased physical activity for chronic weight management in obese (Body Mass Index, or BMI - 30 or more) or overweight (BMI - 27 or more) adults suffering from at least one weight-related co-morbid condition. However, the CHMP maintains a negative opinion on the marketing authorization application (MAA) for Qsymia.

Vivus is also evaluating Qsymia for the treatment of type II diabetes (phase II) and obstructive sleep apnea (phase II).

We remind investors that apart from Qsymia, another weight-loss drug, Arena Pharmaceuticals, Inc.’s (ARNA - Snapshot Report) Belviq, also received approval in the US last year. Orexigen Therapeutics, Inc. (OREX - Analyst Report) is also developing a candidate, Contrave, targeting the lucrative obesity market.

Vivus, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Biopharma companies that currently look more attractive include Cytokinetics, Inc. (CYTK - Snapshot Report) with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%